Featured Research

from universities, journals, and other organizations

Ovarian cancer study offers vital clues for new therapies

Date:
April 22, 2010
Source:
University of Edinburgh
Summary:
Scientists have taken a major step forward in the understanding of ovarian cancer, which could improve treatment for patients with the condition.

Scientists have taken a major step forward in the understanding of ovarian cancer, which could improve treatment for patients with the condition.

Researchers have found that patients with hereditary ovarian cancer -- whose tumours are caused by faulty genes -- are more likely to experience secondary tumours in their liver and spleen. This is despite the fact that their overall prognosis is better than other patients.

In non-hereditary cancer, ovarian tumours tend to remain within the lining of the abdomen and pelvis.

A University of Edinburgh study suggests that ovarian cancer patients whose tumours spread to the solid organs such as the liver and lungs should be tested for the faulty genes -- BRCA1 and BRCA2 -- to ensure they are given the most appropriate treatment.

Researchers say this would improve the detection of these faulty genes as current criteria for genetic testing may miss as many as two-thirds of ovarian cancer patients carrying faulty BRCA genes.

Patients with hereditary tumours, which account for 10 per cent of ovarian cancers, may also be suitable for trials of a new drug called olaparib, which has fewer side-effects than normal cancer treatments.

Improving the identification of BRCA mutations would help relatives of ovarian cancer patients, who may themselves be at increased risk of developing hereditary cancer.

The research is published in the Journal of Clinical Oncology.

Dr Charlie Gourley, who led the research at the University of Edinburgh, said: "We are beginning to understand the importance of tailoring cancer treatments according to the specifics of each patient's tumour. These findings demonstrate that tumours which arise because of defects in the BRCA1 or BRCA2 genes behave differently to other ovarian cancers. This information should also help us to identify the patients carrying these genetic mutations, give them the most effective treatment for their cancer and offer their relatives genetic counselling."


Story Source:

The above story is based on materials provided by University of Edinburgh. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. Gourley, C. O. Michie, P. Roxburgh, T. A. Yap, S. Harden, J. Paul, K. Ragupathy, R. Todd, R. Petty, N. Reed, R. L. Hayward, P. Mitchell, T. Rye, J. H. M. Schellens, J. Lubinski, J. Carmichael, S. B. Kaye, M. Mackean, M. Ferguson. Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype. Journal of Clinical Oncology, 2010; DOI: 10.1200/JCO.2009.25.1082

Cite This Page:

University of Edinburgh. "Ovarian cancer study offers vital clues for new therapies." ScienceDaily. ScienceDaily, 22 April 2010. <www.sciencedaily.com/releases/2010/04/100421102346.htm>.
University of Edinburgh. (2010, April 22). Ovarian cancer study offers vital clues for new therapies. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/04/100421102346.htm
University of Edinburgh. "Ovarian cancer study offers vital clues for new therapies." ScienceDaily. www.sciencedaily.com/releases/2010/04/100421102346.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins